We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst (CPRX) Focused on Development of Pipeline Candidates
Read MoreHide Full Article
We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) on Aug 14.
In fact, Catalyst Pharma is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert-Eaton myasthenic syndrome (LEMS), epilepsy (initially infantile spasms) and Tourette syndrome.
At present, this Coral Gables, FL-based company has two candidates under development – Firdapse and CPP-115.
The company expects to report top-line results from its second phase III study of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in the second half of 2017 and resubmit a new drug application (NDA) before the end of 2017. Earlier in 2016, it received a refusal to file letter from the FDA in connection with the NDA for Firdapse.
Notably, the agency had determined that the company’s NDA was insufficient after a preliminary review. Consequently, Catalyst Pharma was required to conduct additional studies as per the agency’s requirements, in addition to the results of its previously submitted phase III data.
In Oct 2016, it reached an agreement with the FDA under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach to be taken in its second phase III study evaluating Firdapse.
Meanwhile, the company is working on developing Firdapse for additional indications. Catalyst initiated an investigator-sponsored phase II/III study on Firdapse for the symptomatic treatment of MuSK-antibody positive MG in Feb 2016. In Mar 2017, the company reported top-line data from the phase II/III trial.
The potential approval of Firdapse, along with its label expansion will help in generating revenues for the company.
Additionally, Catalyst Pharma is exploring the possibility of developing CPP-115 (a GABA aminotransferase inhibitor) for the treatment of epilepsy (initially infantile spasms) and the treatment of other selected neurological indications such as complex partial seizures and Tourette’s disorder. However, the market for epilepsy treatments is highly competitive and crowded given the presence of products like Pfizer’s (PFE - Free Report) Neurontin and Lyrica, Johnson & Johnson’s (JNJ - Free Report) Topamax, Novartis’ (NVS - Free Report) Trileptal.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars. But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month. Learn the secret >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Catalyst (CPRX) Focused on Development of Pipeline Candidates
We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) on Aug 14.
In fact, Catalyst Pharma is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert-Eaton myasthenic syndrome (LEMS), epilepsy (initially infantile spasms) and Tourette syndrome.
At present, this Coral Gables, FL-based company has two candidates under development – Firdapse and CPP-115.
The company expects to report top-line results from its second phase III study of Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in the second half of 2017 and resubmit a new drug application (NDA) before the end of 2017. Earlier in 2016, it received a refusal to file letter from the FDA in connection with the NDA for Firdapse.
Notably, the agency had determined that the company’s NDA was insufficient after a preliminary review. Consequently, Catalyst Pharma was required to conduct additional studies as per the agency’s requirements, in addition to the results of its previously submitted phase III data.
In Oct 2016, it reached an agreement with the FDA under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach to be taken in its second phase III study evaluating Firdapse.
Meanwhile, the company is working on developing Firdapse for additional indications. Catalyst initiated an investigator-sponsored phase II/III study on Firdapse for the symptomatic treatment of MuSK-antibody positive MG in Feb 2016. In Mar 2017, the company reported top-line data from the phase II/III trial.
The potential approval of Firdapse, along with its label expansion will help in generating revenues for the company.
Additionally, Catalyst Pharma is exploring the possibility of developing CPP-115 (a GABA aminotransferase inhibitor) for the treatment of epilepsy (initially infantile spasms) and the treatment of other selected neurological indications such as complex partial seizures and Tourette’s disorder.
However, the market for epilepsy treatments is highly competitive and crowded given the presence of products like Pfizer’s (PFE - Free Report) Neurontin and Lyrica, Johnson & Johnson’s (JNJ - Free Report) Topamax, Novartis’ (NVS - Free Report) Trileptal.
Zacks' 10-Minute Stock-Picking Secret
Since 1988, the Zacks system has more than doubled the S&P 500 with an average gain of +25% per year. With compounding, rebalancing, and exclusive of fees, it can turn thousands into millions of dollars. But here's something even more remarkable: You can master this proven system without going to a single class or seminar. And then you can apply it to your portfolio in as little as 10 minutes a month. Learn the secret >>